Q1 Earnings Estimate for ALLO Issued By William Blair

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Research analysts at William Blair issued their Q1 2026 earnings estimates for Allogene Therapeutics in a report released on Friday, March 14th. William Blair analyst S. Corwin anticipates that the company will post earnings of ($0.29) per share for the quarter. The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. William Blair also issued estimates for Allogene Therapeutics’ Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.30) EPS and Q4 2026 earnings at ($0.30) EPS.

Other research analysts have also recently issued reports about the stock. Canaccord Genuity Group reissued a “buy” rating and set a $14.00 price objective on shares of Allogene Therapeutics in a report on Friday. Citizens Jmp raised shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a report on Friday. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price objective on shares of Allogene Therapeutics in a report on Friday. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $9.40.

Allogene Therapeutics Stock Performance

Shares of Allogene Therapeutics stock opened at $1.94 on Monday. The company has a 50-day simple moving average of $1.94 and a two-hundred day simple moving average of $2.31. Allogene Therapeutics has a 52-week low of $1.32 and a 52-week high of $4.74. The stock has a market capitalization of $406.76 million, a PE ratio of -1.24 and a beta of 1.02.

Allogene Therapeutics (NASDAQ:ALLO) last issued its earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.06.

Hedge Funds Weigh In On Allogene Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Allogene Therapeutics by 18.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 270,559 shares of the company’s stock worth $576,000 after acquiring an additional 41,753 shares during the last quarter. Two Sigma Advisers LP boosted its position in shares of Allogene Therapeutics by 12.1% during the fourth quarter. Two Sigma Advisers LP now owns 2,702,200 shares of the company’s stock worth $5,756,000 after acquiring an additional 291,800 shares during the last quarter. Rafferty Asset Management LLC boosted its position in shares of Allogene Therapeutics by 15.9% during the fourth quarter. Rafferty Asset Management LLC now owns 367,445 shares of the company’s stock worth $783,000 after acquiring an additional 50,499 shares during the last quarter. Raiffeisen Bank International AG bought a new position in shares of Allogene Therapeutics during the fourth quarter worth $903,000. Finally, ProShare Advisors LLC raised its stake in Allogene Therapeutics by 25.6% during the fourth quarter. ProShare Advisors LLC now owns 46,082 shares of the company’s stock valued at $98,000 after purchasing an additional 9,388 shares in the last quarter. Institutional investors own 83.63% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Zachary Roberts sold 27,199 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total transaction of $48,414.22. Following the completion of the transaction, the executive vice president now owns 488,054 shares in the company, valued at approximately $868,736.12. This represents a 5.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Timothy L. Moore sold 14,746 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $1.71, for a total transaction of $25,215.66. Following the transaction, the insider now owns 250,713 shares of the company’s stock, valued at approximately $428,719.23. This represents a 5.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 52,710 shares of company stock worth $92,125 over the last three months. 24.30% of the stock is currently owned by company insiders.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).